Faculty – Pain Management Summit

Caroline Arout, Ph.D.

Scott L. Dax, Ph.D.
Chief Scientific Officer, CERSCI THERAPEUTICS

view speaker profile

Dr. Scott L. Dax has over 25 years of experience guiding research & development at both large
pharma houses and small biotechnology companies. His leadership roles span chemistry, drug
discovery, pharmacology, technology and intellectual property. Scott is Chief Scientific Officer at
CerSci Therapeutics (www.cersci.com) leading efforts to develop a new generation of non-opioids
to treat acute post-surgical pain and chronic painful diabetic neuropathy. CT-044, a Reactive
Species Decomposition Accelerant (RSDAx) has completed IND-enablement and will enter
clinical trials in 2Q2019.
Scott is also a Project Director at BioMotiv (www.biomotiv.com), a mission-driven development
company associated with The Harrington Project for Discovery & Development, a national
initiative centered at University Hospitals Cleveland Medical Center. The company focus is
accelerating breakthrough discoveries from research institutions into therapeutics for patients.
Previously, Scott served as Chief Technology Officer at Galleon Pharmaceuticals, where he
discovered and designed breathing control modulators to combat respiratory depression caused by
opioid therapy, without compromising analgesia. This work has also led to clinical candidates for
the treatment of narcotic-induced respiratory depression and sleep apnea. Scott’s contributions led
to venture capital investments totaling >$60M. Scott was also a Research Fellow & Analgesics
Research Team Leader at Johnson & Johnson. His team delivered multiple New Chemical Entities
into Early Development, working in the areas of delta-selective and mixed mu / delta opioid
agonists, (Transient Receptor Potential) TRPV1 and TRPM8 antagonists, mono-acylglycerol
lipase inhibitors, N-type calcium channel blockers, NSAIDs (non-steroidal anti-inflammatory
drugs), voltage-gated sodium channel blockers and differentiated tramadol and acetaminophen
analogs. Prior to J&J, Scott held positions at DuPont-Merck and Hoffmann-LaRoche working in
the area of infectious diseases.
Scott is inventor of over 100 issued patents worldwide and more than 100 publications /
presentations in peer-reviewed journal and professional societies. Scott earned his Masters and
Doctorate degrees in chemistry at the University of Michigan and was an NIH post-doctoral
awardee at the University of Wisconsin.

Ashley Elsner, J.D., MBA
Chief Executive Officer and Founder, ARTERY PAY

view speaker profile

Ashley Elsner is CEO and Founder of artery Pay. She is a FinTech expert with 14 years of global financial law, regulation and operations experience. Prior to artery, Ashley cofounded and was Vice President of Operations for Greenshoe Asset Management, an online hedge fund investment platform. She managed the investment process and financial regulatory compliance of $600M+ transactions for Bessemer Venture Partners in their legal and operations group, including interests and responsibilities for LinkedIn’s IPO and Amazon’s acquisition of Diapers.com, among many other exits, and developing the regulatory compliance strategies for India’s new Foreign Venture Capital Investors and Foreign Portfolio Investors laws. Ashley spent 4 years in the financial regulatory group of Sidley Austin LLP, where in addition to managing SEC and state regulatory compliance for its top-ranked fund services team for 800+ hedge funds and 6 publicly traded companies, she was instrumental in managing a year-long internal regulatory audit of an $850B+ international investment bank, clearing the firm’s regulatory record and saving the firm $40M+ in fines. Ashley holds a B.A. with majors in Political Science and Classics from Yale College and a J.D.M.B.A from Northwestern School of Law focused on the intersection of Law and Economics and Northwestern’s Kellogg School of Management with majors in Finance and Innovation and Entrepreneurship.

Danielle Friend, Ph.D.
Director, Science and Regulatory Affairs, BIOTECHNOLOGY INNOVATION ORGANIZATION

Jeffrey Fudin, Pharm.D.
Chief Executive Officer and Chief Medical Officer, REMITIGATE, LLC.

view speaker profile

Dr. Fudin graduated from Albany College of Pharmacy & Health Sciences with his Bachelors Degree and Pharm.D. He is a Fellow to the American College of Clinical Pharmacy, American Society of Health-system Pharmacists, and the Federation of State Medical Boards.
He is managing editor of paindr.com Blog, Co-Editor-At-Large for Practical Pain Management, Senior Editor for Pain Medicine, and peer reviewer for several professional journals. He has over 30 years of direct patent care experience in pain management, and is a national expert in pharmacogenetics, forensic pharmacy and toxicology, and advanced pain therapeutics.
He has well over 300 publications and has participated in several educational films and community outreach forums.
He is Director of the Pharmacy Pain Residency at Stratton Veterans Administration Medical Center and Chief Executive Officer for Remitigate, both in Upstate NY where he also serves on the NY State Board of Medicine Office of Professional Conduct.
He holds several academic faculty positions and is a frequent invited speaker nationally and internationally.

Gary W. Jay, M.D., FAAPM
Clinical Professor, Dept. of Neurology, Division: Headache/Pain at UNC, UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL

view speaker profile

Gary W. Jay, MD is currently Clinical Professor, Dept. of Neurology, Division: Headache/Pain at UNC, Chapel Hill, NC. He previously owned and ran an interdisciplinary Pain, Headache and mTBI NeuroRehabilitation Center for 26 years. He was a founder of the American Academy of Pain Medicine and the American Academy of Pain Management. He has been President of National, Regional and State Pain Medicine Groups. He then went into Pharma, became Chief Medical Officer of 2 Pharmas and a CRO. Dr. Jay then returned to Medicine at UNC. He has published 5 textbooks and over 170 peer reviewed journal articles and textbook chapters. He was also a part of the IMMPACT group while in Pharma. He continues to speak nationally on various topics (Pain, Headache and mTBI) and the issues dealing with the “opioid crisis” and the unanticipated or purposeful patient problems with this.

Steven D. Passik, Ph.D.
Vice President, Scientific Affairs, Education, and Policy, COLLEGIUM PHARMACEUTICALS

view speaker profile

After a 25-year academic and clinical career at Memorial Sloan Kettering Cancer Center, University of Kentucky and Vanderbilt University, Dr. Passik spent the past five and one-half years in the toxicology and most recently the pharmaceutical industry. He is presently the Vice President of Scientific Affairs, Education and Policy at Collegium Pharmaceuticals. His research has focused on the interface of pain management and addiction and psychiatric aspects of cancer and non-cancer pain and symptom management. He has served as editor and reviewer for multiple journals in pain and psycho-oncology. He has authored over 200 scholarly publications.

Tim Peara
President and Finance Director, BRIDGE THERAPEUTICS

Joseph V. Pergolizzi, M.D.

view speaker profile

Dr. Joseph Pergolizzi, M.D. is an internationally renowned perioperative and pain specialist, well-versed in the multiplicity of issues confronting patients and caregivers in acute and chronic pain. He is currently a senior partner at Naples Anesthesia and Pain Associates, Inc. In clinical practice, he combines the latest medical advances and scientific breakthroughs with his profound professional compassion for patients facing painful, life-altering conditions. As a physician, inventor, research scientist and advocate for pain patients, Dr. Pergolizzi has leveraged his significant medical, regulatory and business expertise to build a strong track record of success within the healthcare industry.

Previously, Dr. Pergolizzi served as an adjunct assistant professor in the Department of Medicine at Johns Hopkins University School of Medicine, a committee member of the Food and Drug Administration’s Safe Use Initiative and as a Special Government Employee for the Veterans Health Administration. He is a member of various advisory boards and medical societies, as well as institutional committees, including Medical Errors Committee and Pharmacy and Therapeutics Committee. Dr. Pergolizzi is the author of over 250 peer reviewed articles, abstracts, platform presentations and book chapters, and has been awarded the American Medical Association Physician Recognition Award with Commendation.

Robert Raffa, Ph.D.
Chief Scientific Officer, NEUMENTUM, INC.

view speaker profile

Dr. Raffa is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He earned bachelor’s degrees in Chemical Engineering and in Physiological Psychology (both from the University of Delaware), master’s degrees in Biomedical Engineering (from Drexel University) and Toxicology (Thomas Jefferson University), and a doctorate in Pharmacology (Temple University School of Medicine). He was a Research Fellow and a Team Co-Leader for analgesics drug discovery at Johnson & Johnson, where he was pivotal in the elucidation of the mechanism of action and development of the analgesic drug tramadol (Ultram™). He is a cofounder of CaRafe Drug Innovation and the CSO of Neumentum Inc, both companies directed to the discovery and development of non-opioid analgesics. He is the co-holder of several patents, including for the combination of tramadol plus acetaminophen (Ultracet™). He has published more than 300 papers in refereed journals, and co-authored or edited several books on pharmacology and thermodynamics, and is a Co-Editor of Journal of Clinical Pharmacy and Therapeutics. He is a past president of the Mid-Atlantic Pharmacology Society of ASPET and is the recipient of research and teaching awards. He lectures and consults worldwide on pain pathways and analgesics.

Sebastian Schwier, Ph.D.
Director, Transfer and Integration Management, GRUNENTHAL

view speaker profile

Sebastian Schwier, Ph.D., is Project Director within the Innovation Unit Devices and Technologies at Grunenthal GmbH in Aachen, Germany. He is responsible for leading CMC development teams including projects with Grunenthal’s INTAC® technology. Further, he is driving transfer activities and is part of the Category One Focus group for abuse-deterrent formulations.

Dr. Schwier joined Grunenthal’s corporate headquarters in Aachen, Germany in 2008 as a laboratory head in the Pharmaceutical Development department developing abuse-deterrent formulations (ADFs). Since 2012 he is responsible as CMC project leader for the development of ADFs internally as well as in collaboration with partners. In addition, he steers collaborations with partners on developing, manufacturing and testing ADFs.

Dr. Schwier received his degree as Pharmacist and later achieved a Ph.D. in Pharmaceutical Technology and Biopharmaceutics from the University of Munster, Germany.

Joe Stauffer
Chief Medical Officer, INHERIS BIOPHARMA

Alex Wasyl
Chief Executive Officer, NEXIEN BIOPHARMA

view speaker profile

Alex has acquired a decade+ of experience in several industry verticals including pharmaceutical, biotechnology, drug delivery systems, food, beverage, nutritional supplements, nutraceuticals, consumer products, industrial chemicals, and green cleaning technology.

Alex possesses an exceptional background in business, marketing, nutritional sciences, biology, biochemistry, and related life sciences.

Debra R. Wilson, Ph.D.

John A. Zebala M.D., Ph.D.
Chief Executive Officer and President, SYNTRIX PHARMACEUTICALS